China-based OriCell Therapeutics has closed a USD 110 million Pre-IPO financing round to support the global development of its cell therapy pipeline. The round was co-led by Vivo Capital, the Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from E-Town Capital, Lucion Capital, ELiKon Venture, NGS Super, Talon Capital, and other institutional investors. The funds will accelerate international multi-centre clinical trials for the company's core assets, strengthen its technology platform, and prepare for a future IPO.

Oricell's lead candidate, Ori-C101, is an autologous CAR-T therapy targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). Having completed Phase I studies, the candidate is preparing to enter pivotal trials with the potential to become the first CAR-T therapy approved for liver cancer. The company is also advancing a pipeline of next-generation CAR-T candidates, including in vivo CAR-T programs, leveraging its proprietary antibody discovery and cell engineering platforms.

PharmCube's MedAlpha® database shows that OriCell closed five previous funding rounds, totalling USD 392.53m in funds raised so far. Click here to request a free trial for MedAlpha®.